Comparative Assessment of the Accuracy of Cytological and Histologic Biopsies in the Diagnosis of Canine Bone Lesions by Sabattini, S. et al.
Comparative Assessment of the Accuracy of Cytological and
Histologic Biopsies in the Diagnosis of Canine Bone Lesions
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Background: Osteosarcoma (OSA) should be differentiated from other less frequent primary bone neoplasms, metastatic
disease, and tumor-like lesions, as treatment and prognosis can vary accordingly. Hence, a preoperative histologic diagnosis
is generally preferred. This requires collection of multiple biopsies under general anesthesia, with possible complications,
including pathological fractures. Fine-needle aspiration cytology would allow an earlier diagnosis with a significant reduction
of discomfort and morbidity.
Hypothesis/Objectives: The aim of this study was to compare the accuracy of cytological and histologic biopsies in the
diagnosis of canine osteodestructive lesions.
Animals: Sixty-eight dogs with bone lesions.
Methods: Retrospective study. Accuracy was assessed by comparing the former diagnosis with the final histologic diagno-
sis on surgical or post-mortem samples or, in the case of non-neoplastic lesions, with follow-up information.
Results: The study included 50 primary malignant bone tumors (40 OSAs, 5 chondrosarcomas, 2 fibrosarcomas, and 3
poorly differentiated sarcomas), 6 carcinoma metastases, and 12 non-neoplastic lesions. Accuracy was 83% for cytology (sen-
sitivity, 83.3%; specificity, 80%) and 82.1% for histology (sensitivity, 72.2%; specificity, 100%). Tumor type was correctly
identified cytologically and histologically in 50 and 55.5% of cases, respectively.
Conclusions and Clinical Importance: The accuracy of cytology was similar to histology, even in the determination of
tumor type. In no case was a benign lesion diagnosed as malignant on cytology. This is the most important error to prevent,
as treatment for malignant bone tumors includes aggressive surgery. Being a reliable diagnostic method, cytology should be
further considered to aid decisions in the preoperative setting of canine bone lesions.
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The majority of destructive bone lesions in dogs areneoplastic in origin, and almost all primary bone
tumors are malignant.1 Osteosarcoma (OSA) accounts
for up to 85% of primary skeletal malignancies, fol-
lowed by chondrosarcoma (CSA), hemangiosarcoma
(HSA), fibrosarcoma (FSA), myeloma, and lymphoma.
Additionally, the skeleton can be affected by metastatic
lesions. A presumptive diagnosis of bone malignancy
can be based on signalment, history, physical
examination, and radiographic changes, including severe
osteolysis and periosteal reaction.1 However, several
benign diseases might resemble malignant tumors both
clinically and radiographically, such as osteomyelitis,
traumatic, and dysplastic lesions, thus needing to be
included in the differential diagnosis.2,3
Although aggressive treatment is required for all pri-
mary malignant bone neoplasms, therapeutic decisions, and
prognosis might differ considerably according to tumor
type. The median survival time for dogs with appendicular
OSA treated with limb amputation and chemotherapy
ranges from 8 to 18 months.4–7 Primary HSA of bone is
an equally aggressive tumor, with median survival times
<1 year.1 Conversely, CSA and FSA share a lower meta-
static potential and surgery alone might be curative.1,8
Histologic interpretation of bone biopsies is usually
recommended to obtain a preoperative diagnosis. Nev-
ertheless, this procedure requires general anesthesia and
complications might occur, including pathological frac-
tures, increased pain, hematoma, and local seeding of
tumor cells;9–11 the latter might be a serious concern if
a limb-sparing procedure has been planned. In addition,
histologic results are not always conclusive, because
biopsies might be of inadequate size or quality or not
sufficiently representative.3
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Fine-needle aspiration cytology (FNAC) offers several
advantages over histologic biopsy (HB), including mini-
mal invasiveness, lower risk of complications, ease of
sample collection, and rapid results.12 However, it also
has several limitations, including the inability to evalu-
ate tissue architecture; this might prompt a generic
diagnosis of malignancy without further classification of
tumor type.13–15 In addition, clinicians can be concerned
about the difficulty in performing an adequate cytologi-
cal sampling from a bone lesion, because of the chal-
lenge of penetrating the bone cortex.
To determine the reliability of FNAC as a diagnostic
procedure for canine bone lesions, we reviewed this
experience over the past 15 years at our institutions.
The accuracy of cytology was compared with that of
HB. In particular, we evaluated the ability of both
methods to discriminate between benign and malignant
lesions and, among the latter, to correctly identify
tumor type. Additionally, we evaluated the potential
effects of multiple clinicopathological variables on
FNAC accuracy, to determine the most appropriate use
for this procedure.
Materials and Methods
Case Selection
A retrospective study was performed on canine osteodestructive
lesions diagnosed from 2000 to 2016 at the Department of Veteri-
nary Medical Sciences (University of Bologna) and the Depart-
ment of Veterinary Sciences (University of Turin).
Dogs receiving a FNAC, a HB or both for diagnostic purposes
were considered for inclusion. The cases with a final diagnosis on
a surgical or post-mortem histologic sample were selected for
inclusion.
If the first diagnosis was consistent with a benign or a non-neo-
plastic process, for which surgery was not indicated, the correct-
ness of diagnosis was assessed by evaluating the long-term
outcome.
Primary cutaneous or oral tumors with local bone infiltration
(eg, squamous cell carcinoma, melanoma) were not included.
The radiographic images were retrospectively evaluated by 2 of
the authors (PB, OC) to assess the amount of bone lysis and peri-
osteal reaction. The amount of bone lysis was estimated in propor-
tion to the entire lesion and classified as mild (<20%), moderate
(20–50%), or severe (>50%). Periosteal reaction was assessed by
comparing the thickness of the reaction (Rt) with the thickness of
unaffected cortex (Ct) and classified as absent, mild (Rt < Ct),
moderate (Rt = Ct), or severe (Rt > Ct).
The cytological samples were collected under local anesthesia (if
necessary) by fine-needle aspiration with 21–22 Gauge needles and
2.5–5-mL syringes. The sampling site was selected by radiographic
examination and palpation, in order to collect cells from lesser-
mineralized areas and to introduce the needle where the periosteal
reaction was minimal. The collected material was then deposited
and smeared on glass slides, which were allowed to air-dry, stained
with May–Gr€unwald–Giemsa, and cover slipped.
The histologic samples were collected by means of an 8–11
gauge Jamshidi needle. The biopsy site was planned based on
radiographic findings. Dogs underwent general anesthesia and
were surgically prepared. After practicing a 2–3 mm skin incision
with a scalpel, the cannula with the stylet locked in place was
advanced through the soft tissue until bone was reached. Then the
stylet was removed, and the bone cortex was penetrated with the
cannula with the aid of rotation movements, being careful not to
penetrate the cortex on the opposite side, and then withdrawn.
The obtained specimens were expelled from the cannula with a
probe. When feasible, the procedure was repeated through the
same incision with a different redirection of the instrument. Histo-
logic slides were obtained after formalin-fixation, decalcification (if
necessary), and paraffin embedding. Sections were cut at 4 lm and
stained with hematoxylin and eosin.
Microscopic Evaluation
All FNAC and HB preparations were re-examined (SS, AR,
SD) without knowledge of the previous and final diagnoses. Diag-
nosis was by consensus. The pathologists were not blinded to
imaging studies and clinical findings.
The evaluated cytological variables included cellularity (classi-
fied as absent, low, moderate, or abundant), blood contamination
(classified as absent, low, moderate, or abundant), prevalent cell
population and its characteristics, secondary cell populations and
noncellular material.
The histologic assessment of HBs (first histologic diagnosis) and
of surgical or post-mortem samples (final diagnosis) was carried
out according to the schemes of the World Health Organization
(WHO).16 For sarcomas, the histologic grade of malignancy was
assessed according to previously published criteria.17–19 Osteosar-
comas were further divided into 2 categories on the basis of
osteoid production (productive and poorly productive).
Statistical Analysis
Accuracy, sensitivity, specificity, positive, and negative predic-
tive values of FNAC and HB were assessed by comparing the first
diagnosis (cytological or histologic) with the final histologic diag-
nosis on surgical or post-mortem samples, or with the clinical out-
come if surgery was not performed. In particular, we evaluated the
diagnostic accuracy of both methods in correctly identifying malig-
nant neoplastic lesions and, within these, in diagnosing the specific
tumor type. The results were presented in a confusion matrix. The
confidence intervals of sensitivity and specificity were analyzed by
the receiver operating characteristics (ROC) method. The effects of
lesion site, tumor diameter, bone lysis, periosteal reaction, cellular-
ity, blood contamination, tumor grade, and osteoid production on
the possibility to obtain a correct cytological diagnosis were fur-
ther evaluated with Fisher’s exact test. Data were analyzed by
SPSS statistical softwarea. P values < .05 were considered signifi-
cant.
Statement of Animal Care
This study is a retrospective investigation carried out on
archived tissue samples from canine bone lesions. As the research
did not influence any therapeutic decision, approval by an Ethics
Committee was not required. All the examined samples were col-
lected for diagnostic purposes as part of routine standard care.
Owners gave informed consent to the use of clinical data and
stored biological samples for teaching and research purposes.
Results
Study Population
Review of medical records identified 68 cases of
canine bone lesions that were sampled by FNAC
(n = 53) or HB (n = 28). Thirteen cases were sampled
by both methods. Eighteen dogs were mixed-breed;
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among purebred dogs, the most represented were Boxer
(n = 7), Rottweiler (n = 7), German shepherd (n = 6),
and Labrador retriever (n = 4). There were 35 males
(51.5%; 4 castrated) and 33 females (48.5%; 17 spayed).
The median age was 8.6 years (range, 1.5–14.3), and the
median weight was 30.5 kg (range, 4–68). Lesions
involved the appendicular skeleton in 58 cases (85.3%)
and the axial skeleton in 10 (14.7%).
Radiographs were available for review in 50 cases
(73.5%). Bone lysis was graded as mild in 8 cases
(16%), moderate in 15 cases (30%), and severe in 27
cases (54%). Periosteal reaction was classified as absent
in 11 cases (22%), mild in 13 cases (26%), moderate in
12 cases (24%), and severe in 14 cases (28%). The med-
ian diameter of lesions was 5 cm (range, 1–25 cm).
Final Diagnoses
The final diagnosis was obtained by the histologic
examination of surgical or post-mortem samples in 58
cases. Benign lesions consisted of 1 granulomatous
mycotic osteomyelitis and 1 foreign body (vegetal mate-
rial) osteomyelitis. Malignant lesions included 40 OSAs,
5 CSAs, 2 FSAs, 3 poorly differentiated sarcomas, and
6 carcinoma metastases (mammary carcinoma, n = 5;
tonsillar squamous cell carcinoma, n = 1). Seven sarco-
mas (14%) were grade I, 21 (42%) were grade II, and
22 (44%) were grade III. There were 28 osteoblastic, 5
chondroblastic, 3 fibroblastic, 2 giant cell, and 2 poorly
differentiated OSAs. Twenty-four (60%) were classified
as osteoproductive and 16 (40%) as poorlyosteoproduc-
tive.
In the remaining 10 cases, surgical or post-mortem
samples were not available, but a malignant process
was excluded based on the evidence of no clinical pro-
gression and long-term survival with no surgery or
chemotherapy (median, 4 years; range, 1–6 years). Two
of these cases (20%) were sampled by FNAC, 6 (60%)
by HB and 2 (20%) by both methods. Among FNACs,
1 case was nondiagnostic, 2 were diagnosed as
osteomyelitis and one as reactive bone. Among HBs, 1
case was diagnosed as osteochondroma, 1 as
osteomyelitis, 4 as reactive bone and 2 as normal bone.
Histologic Biopsy Diagnoses
Twenty-eight lesions were sampled by HB. The mean
number of biopsy samples per case was 3 (range, 1–7).
The accuracy of HB compared with the final diagnoses
was 82.1%. In particular, 10 of 10 benign lesions (speci-
ficity: 100%; 95% CI: 69.2–100%) and 13 of 18 malig-
nant lesions (sensitivity: 72.2%; 95% CI: 46.5–90.3%)
were correctly identified. Positive and negative predic-
tive values were 100 and 66.7%, respectively. The area
under the curve was 0.861 (95% CI: 0.723–0.999;
P = .002) (Fig 1). The 5 unidentified cases (27.8%)
included 1 OSA diagnosed as osteomyelitis, 2 OSAs,
and 1 FSA diagnosed as reactive bone and 1 CSA diag-
nosed as chondroma. Among malignant lesions, HB
correctly identified tumor type in 10 cases (55.5%),
whereas in 3 OSA cases (16.7%), a generic diagnosis of
sarcoma was made. All metastatic lesions (n = 3) were
correctly identified (Figs 2, 3; Table 1).
Fine-Needle Aspiration Cytology Diagnoses
Fifty-three lesions were sampled by FNAC. Repre-
sentative examples of cytological specimens are pro-
vided in Figure 4. The mean number of slides per case
was 5 (range, 1–17). Cellularity was poor in 16 cases
(30.2%) and moderate to high in the remaining 37 cases
Fig 1. Confusion matrix of actual and predicted malignancy in a
series of canine bone lesions sampled by fine-needle aspiration
cytology or histologic biopsy.
Fig 2. Diagnostic accuracy of fine-needle aspiration cytology and
histologic biopsy observed in 68 cases of canine benign and malig-
nant osteodestructive lesions.
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(69.8%). Blood contamination was high in 25 cases
(47.2%) and low to moderate in 28 (52.8%). Overall
accuracy for FNAC was 83%, with 4 of 5 benign
lesions (specificity: 80%; 95% CI: 28.4–99.5%) and 40
of 48 malignant lesions (sensitivity: 83.3%; 95% CI:
69.8–92.5%) correctly identified. Positive and negative
predictive values were 97.6 and 33.3%, respectively. The
area under the curve was 0.817 (95% CI: 0.603–1.030;
P = .002) (Fig 1). All the 9 unidentified cases (17%; 7
OSAs, 1 poorly differentiated sarcoma and 1 benign
lesion) had been considered inadequate for a cytological
diagnosis because of insufficient cellularity. Among
malignant lesions, cytology correctly identified tumor
type in 24 cases (50%). In other 16 cases, a diagnosis of
malignancy was reached, but tumor type was not identi-
fied, or it was incorrect. In particular, 11 cases (10
OSAs and 1 FSA) were generically diagnosed as sarco-
mas, 2 chondroblastic OSAs were diagnosed as CSAs, 1
poorly differentiated sarcoma and 1 CSA were diag-
nosed as OSA, and 1 OSA was diagnosed as giant cell
tumor of bone. All the 5 cases of bone metastasis from
epithelial tumors were correctly diagnosed on cytology
(Figs 2, 3; Table 1).
The proportion of correct diagnoses did not differ
significantly according to tumor location (appendicular
or axial), tumor diameter (≤ o > than the median
value), the amount of osteolysis or periosteal reaction,
and tumor grade. Considering the characteristics of the
smear, poor cellularity was significantly associated with
a lower accuracy (P < .001). When OSAs were divided
according to the production of osteoid matrix evaluated
on surgical or post-mortem samples, poorlyproductive
tumors were correctly diagnosed in 35.7% of cases,
whereas productive OSAs were recognized in 52.4% of
cases; however, this difference was not statistically sig-
nificant (Table 2).
Concurrent FNAC and HB Diagnoses
Thirteen cases (3 benign and 10 malignant lesions)
were sampled with both FNAC and HB. Concordance
between the 2 methods was observed in 9 cases
(69.2%), 2 benign, and 7 malignant lesions. In all the
13 cases, at least 1 of the 2 techniques provided the cor-
rect diagnosis.
Discussion
The aim of this study was to compare the diagnostic
accuracy of bone cytology with that of HB, using the
Fig 3. Diagnostic accuracy of fine-needle aspiration cytology and histologic biopsy observed in 56 cases of canine malignant osteodestruc-
tive lesions grouped according to tumor type.
Table 1. Comparative assessment of the accuracy of
fine-needle aspiration cytology (FNAC) and histologic
biopsies (HB) in the diagnosis of canine bone lesions.
FNAC (%) HB (%)
Total number of cases 53 28
Proportion of cases correctly
identified as malignant
or benign (accuracy)
44/53 (83) 23/28 (82.1)
Nondiagnostic cases 9/53 (17) –
Malignant lesions 48 18
Proportion of malignant
lesions correctly
identified (sensitivity)
40/48 (83.3) 13/18 (72.2)
Tumor type correctly diagnosed 24/48 (50) 10/18 (55.5)
Osteosarcomas 15/35 (42.8) 5/11 (45.4)
Chondrosarcomas 3/4 (75) 2/3 (66.7)
Fibrosarcomas 0/1 (0) 0/1 (0)
Poorly differentiated sarcomas 1/3 (33.3) –
Bone metastasis 5/5 (100) 3/3 (100)
Benign lesions 5 10
Proportion of benign lesions
correctly identified (specificity)
4/5 (80) 10/10 (100)
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histologic diagnosis on surgical or post-mortem samples
as the gold standard. Results demonstrated that both
FNAC and HB are equally reliable diagnostic tech-
niques in the preoperative diagnosis of canine osteode-
structive lesions. Sampling errors were determinant in
affecting the accuracy of both techniques. The main
limits were related to the lack of recognition of malig-
nant lesions, ie, false negatives. Conversely, in no case a
benign lesion was diagnosed as malignant. This type of
error is the most important to prevent, as the treatment
of choice for malignant bone tumors is radical surgery.
Quite surprisingly, the 2 methods were equivalent also
in the determination of tumor type. Thus, the advan-
tages of FNAC, namely, timeliness, ease of perfor-
mance, and decreased cost and discomfort, make
attempting a diagnosis by this technique worthwhile. In
those cases where cytology fails to yield a diagnostic
sample, a traditional biopsy can be performed, because
the greatest chance of success can be achieved by a
combined use of both procedures.
A B
C D
E F
G H
Fig 4. Fine-needle aspirates of canine osteodestructive lesions. (A) Osteosarcoma (OSA). Pleomorphic population of malignant osteoblasts
associated with pink strands of osteoid matrix. Cells are oval to elongated, with peripheral nuclei and prominent nucleoli. Few mitoses are
observed. (B) OSA, giant cell type. Giant multinucleated and binucleated cells admixed with atypical mononuclear cells. (C) Chondrosar-
coma. Neoplastic chondroblasts interspersed in a large amount of magenta extracellular matrix. Cell cytoplasm contains few clear vacuoles
and fine pink granulation. Nuclei are large, round, with coarse chromatin. (D) Poorly differentiated sarcoma. Scattered spindle-shaped cells
with prominent anisokaryosis and nuclear atypia. (E) Carcinoma metastasis. Clusters of disorderly arranged epithelial cells with variably
sized cytoplasmic vacuoles and moderate anisokaryosis. (F) Suppurative, septic osteomyelistis. Numerous degenerated neutrophils with
both intracellular and extracellular bacterial cocci. (G) Pyogranulomatous osteomyelitis. A mixed population of inflammatory cells includ-
ing large epithelioid macrophages, moderately degenerate neutrophils, plasma cells, and few lymphocytes. (H) Granulomatous, mycotic
osteomyelitis. Several negative images of poorly staining fungal hyphae, along with multinucleated giant cells, epithelioid macrophages,
lymphocytes, and cellular debris. Hyphae stain pink with Periodic Acid-Schiff (inset). Fungal culture was positive for Aspergillus terreus.
May–Gr€unwald–Giemsa and Periodic Acid-Schiff (H, inset). Bars, 25 lm (A, B, D, F–H) and 50 lm (C, E).
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Understanding the diagnostic performance of cytol-
ogy and histopathology for specific tissues and lesions
can help choosing between FNAC and biopsy in a
given clinical situation.12 For bone lesions, the accuracy
of preoperative diagnosis is particularly important.
Thus, they require a diagnostic procedure allowing not
only the differentiation between benign and malignant
processes, but also between OSA, other primary bone
tumors with a less aggressive biologic behavior and
metastatic lesions.3,19
Histologic examination is presently considered the
gold standard method. The assessment of tissue archi-
tecture and relationships with surrounding tissues
should allow a better identification of tumor type.
Potential limitations of incisional biopsies are the small
sample size, with limited tissue available for examina-
tion, and a high frequency of crush artifacts or morpho-
logic artifacts because of tissue decalcification.
Additionally, the sampled material might not be repre-
sentative of the primary pathologic process, because of
necrotic areas, hematic lacunae, or reactive bone.
The advantages of cytology over histology can be, in
addition to a lower morbidity, the possibility to carry
out sampling at multiple points, increasing the likeli-
hood of collecting neoplastic cells, and the possibility to
observe the obtained preparations extemporarily, and
repeat sampling at need. Moreover, the morphology of
collected material is usually good, as it does not require
decalcification. The intrinsic limitation of cytological
diagnosis resides in the impossibility to appraise tissue
architecture. Thus, bone cytology might yield a generic
diagnosis of sarcoma and not allow for a further classifi-
cation of tumor type. Another possible limitation is the
fact that certain bone lesions exfoliate with difficulty,
thus providing preparations with poor cellularity.13,14
In this study, the accuracy of cytology (83%) in dis-
criminating between benign and malignant lesions was
similar to that of histologic biopsies (82.1%). With both
techniques, in no case was a benign lesion diagnosed as
malignant, although the specificity of cytology was
decreased because of 1 nondiagnostic case. In compar-
ison, sensitivity was lower, with 16.7% of malignant
lesions not identified cytologically and 27.8% histologi-
cally. The presented accuracy of bone cytology is com-
parable to the data obtained in previous studies. In
human medicine, cytology shows a sensitivity and speci-
ficity of 86 and 94.7%, respectively, and an accuracy of
83% in identifying a primary malignant bone
tumor.20,21
Similar studies in veterinary medicine reports accura-
cies between 97 and 69% in differentiating benign and
malignant lesions.11,15,22,23 Several elements partially
limit the interpretation and comparison of the results
with these studies. In some of those, the histologic diag-
nosis being compared with cytological diagnosis was
indifferently obtained from surgical/post-mortem sam-
ples or from small incisional biopsies. This might obvi-
ously affect the reliability of results, since, as we
observed in this study, the preoperative biopsy does not
always correspond to the definitive histologic diagnosis.
Additionally, most authors report a generic diagnosis of
cancer, but it is not clearly specified whether the tumor
type was identified. Finally, some authors have elected to
exclude nondiagnostic cases from the assessment of accu-
racy, whereas others have included them. In this study,
we considered appropriate to maintain nondiagnostic
samples in data analysis, because the possibility of
obtaining adequate cytological preparations from a bone
lesion was among the hypotheses of the study and,
indeed, sample inadequacy plays an important role in
limiting the diagnostic accuracy of cytology. According
to this results, the percentage of cases in which tumor
type was correctly identified was limited and, quite sur-
prisingly, similar between histology (55.5%) and cytol-
ogy (50%). With both methods, most CSAs and all
epithelial metastatic lesions were correctly identified.
Conversely, more than half of the OSA cases were gener-
ically diagnosed as “sarcomas”, both cytologically and
histologically. A generic preoperative diagnosis of malig-
nant primary bone tumor might not affect the type of
surgical approach; however, it might limit the possibility
to formulate a prognosis and impair clinical decisions.
Both the histologic and cytological diagnoses of OSA
are based on the detection of mesenchymal cells with
malignant features in combination with osteoid. The
amount of osteoid seemed to impact the likelihood of
Table 2. Influence of clinicopathological parameters
on the accuracy of fine-needle aspiration cytology
(FNAC) in the diagnosis of canine bone lesions.
Variable Evaluation
Proportion of
Pathologic
Processes
Identified
(Accuracy) (%) P
Lesion site
Appendicular Clinical 35/43 (81.4) .672
Axial 9/10 (90)
Tumor diameter
≤5 cm Radiographic 19/21 (90.5) .260
>5 cm 19/25 (76)
Bone lysis
Mild Radiographic 5/6 (83.3) .720
Moderate to severe 27/33 (81.8)
Periosteal reaction
Absent to mild Radiographic 14/19 (73.3) .235
Moderate to severe 18/20 (90)
Cellularity
Poor Cytological 7/16 (43.8) <.001
Moderate to high 37/37 (100)
Blood contamination
High Cytological 19/25 (76) .278
Low to moderate 25/28 (89.3)
Tumor grade (sarcomas)
I/II Histologic
(surgical/
post-mortem
sample)
18/23 (78.3) .704
III 17/20 (85)
Osteoid production (osteosarcomas)
Productive Histologic
(surgical/
post-mortem
sample)
11/21 (52.4) .491
Poorly productive 5/14 (35.7)
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identifying OSAs on cytology, but not systematically.
The finding of osteoid is a reliable proof of the origin
of the neoplasm, but it not always possible, even in the
case of productive tumors, presumably because of the
large variability among different areas of the same
tumor. Indeed, OSAs can present a very heterogeneous
histologic appearance, resulting in areas with variable
differentiation, which might resemble other mesenchy-
mal tumors (CSA, FSA, HSA). Additionally, in some
cases it might be difficult to distinguish osteoid from a
fibrous or chondroid matrix.3,24 Additional staining
methods can be applied to allow the differentiation of
OSA from other mesenchymal tumors, that is, cyto-
chemical staining for alkaline phosphatase or immuno-
histochemical staining for specific bone matrix proteins
like osteonectin and osteocalcin. The main limitation of
these methods is that reactive osteoblasts will stain posi-
tive as well, so criteria of malignancy must be
assessed.15,25–27
Overall, the concordance of cytology and histology
with the final diagnosis was not completely satisfactory.
Depending on the employed technique, this can be
attributed to different causes. Four of 5 histologic diag-
nostic errors were due to a diagnosis of reactive bone
tissue instead of a neoplastic process. In these cases, the
pathologist correctly identified the process occurring in
the observed preparations; however, the correct diagno-
sis was not reached because the sampling missed the
neoplastic lesion. Indeed, the tissue surrounding a bone
lesion is frequently involved in severe reactive processes,
which might mislead the diagnostic judgment in case of
superficial sampling.2,3,28 As previously demonstrated,
sampling the central areas provides the greatest accu-
racy rate in the case of destructive bone lesions.28 Cyto-
logical mistakes accounted for 17% of the total and
were in all cases due to inconclusive diagnoses because
of hypocellular aspirates. In these cases, an extemporary
evaluation of the cellularity of the samples either by
macroscopic examination or by rapid stains could have
helped to recognize the inadequacy of aspirates, and
highlight the opportunity to obtain more samples at dif-
ferent sites. It has been reported that the cellularity of
samples can affect not only the adequacy of prepara-
tions but also the level of accuracy in diagnostic cases.23
However, the judgment of adequacy is subjective and
often influenced by the experience of the pathologist
and by the availability of clinical and radiographic data
supporting the diagnostic evidence.
Notably, over 90% of the diagnostic errors in this
study, both histologic and cytological, were attributable
to sampling rather than interpretation. This demon-
strates that a correct sampling technique, an adequate
number of samples and the choice of sampling sites are
at least as relevant as the pathologist’s experience. Most
importantly, in the cases where both cytological and
histological samples were available, at least 1 of the 2
methods allowed to reach the correct diagnosis, suggest-
ing that the greatest chance of success can be obtained
by combining these techniques.
There are several limitations to the interpretation of
these data. Because this was a retrospective study that
required cytology and histopathology, it was biased
toward neoplastic lesions, because they are more
likely to have biopsy or surgery performed. Conse-
quently, we had a proportionally lower number of
cases with a diagnosis of inflammation or non-neo-
plastic proliferation. These included 10 cases with no
final confirmation on surgical or post-mortem sam-
ples, in which the lack of malignancy was only
hypothesized based on long-term survival and no pro-
gression of clinical and radiographic signs. Neverthe-
less, it must be stated that follow-up alone cannot
completely rule out a malignant process. Finally, the
number of cases in which cytology and HB were both
performed was limited, thereby reducing the possibil-
ity to compare the utility of these techniques on the
same lesions.
Footnote
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